Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Defensin (HNP-1)30 residuesACYCRIPACIAGERRYGTCIYQGRLWAFCCEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: HNP-1, HNP1, Human Neutrophil Defensin 1
Over 1,000 PubMed papers cover defensin biology, yet zero human clinical trials have been completed. Human Neutrophil Peptide-1 (HNP-1) is a 30-amino-acid alpha-defensin that makes up 5 to 7 percent of total neutrophil protein. It kills bacteria, fungi, and enveloped viruses by punching holes in their membranes. The catch: no one has formally tested exogenous HNP-1 in humans as a therapeutic agent. Manufacturing is the bottleneck. Three intramolecular disulfide bonds must form in a precise pattern, making production expensive and quality verification difficult. Immunology researchers studying innate defense mechanisms use it most, typically sourced from Bachem or AnaSpec at roughly $250 per 0.1 mg.
Human Neutrophil Peptide-1 (HNP-1, CAS 98663-02-0) is an alpha-defensin stored in neutrophil azurophilic granules and one of the first-line antimicrobial peptides your immune system deploys. Over a thousand published papers exist, but not a single human clinical trial. When neutrophils detect infection, they release HNP-1 in bulk. The peptide carries a net +3 charge at physiological pH. That cationic charge pulls it toward the negatively charged membranes of bacteria, fungi, and enveloped viruses. Once bound, HNP-1 oligomerizes, inserts into the lipid bilayer, and forms pores that collapse transmembrane gradients. The result is osmotic lysis. The peptide also does something more interesting. It recruits immune cells. HNP-1 binds CCR6 on immature dendritic cells and memory T cells, functioning as a chemokine. It promotes dendritic cell maturation, upregulates MHC class II expression, and activates macrophages through TLR4-dependent NF-kB signaling. This means HNP-1 connects innate and adaptive immunity; it kills pathogens directly and then calls in reinforcements. Anti-HIV activity has been confirmed in cell-free assays (Chang et al., 2005)[1]. But Demirkhanyan et al. (2012)[2] showed HNP-1 can increase HIV infectivity, and a 2015 study [3] found HNP-1 disrupts epithelial tight junctions, increasing HIV traversal of mucosal barriers. That paradox alone makes clinical development complicated. Research-grade HNP-1 costs $250 to $400 per 0.1 mg from suppliers like Bachem and Sigma-Aldrich. No compounded versions exist. The gray market has essentially zero availability. Anyone exploring this compound is working in a serious research context, not buying vials from a peptide vendor.
HNP-1 works through two distinct pathways: direct membrane destruction and receptor-mediated immune signaling. The antimicrobial mechanism is straightforward. HNP-1 carries a net +3 cationic charge. Microbial membranes are rich in anionic phospholipids; mammalian membranes are mostly zwitterionic. That charge difference creates selectivity. HNP-1 binds the microbial surface, oligomerizes, and inserts into the bilayer to form multimeric pores. Transmembrane gradients collapse. The cell lyses. Gram-negative bacteria add a step. HNP-1 first displaces the Mg2+ and Ca2+ cations stabilizing LPS in the outer membrane. Only after breaching that barrier does it reach the inner membrane for pore formation. Against enveloped viruses like HIV-1, HNP-1 disrupts glycoprotein-mediated fusion and damages the viral lipid envelope directly [1]. The immunomodulatory pathway runs through CCR6 receptors on immature dendritic cells and memory T cells. HNP-1 is a chemoattractant, pulling these cells toward infection sites. It then promotes dendritic cell maturation by upregulating CD80, CD86, CD83, and MHC class II (Yang et al., 1999)[4]. Macrophage activation occurs via TLR4-dependent signaling, increasing phagocytic capacity and triggering NF-kB-driven release of TNF-alpha, IL-1beta, and IL-6. HNP-1 also activates complement by binding C1q and initiating the classical pathway.
No human clinical trials exist. ~1,000 PubMed publications cover defensin biology, but all human-relevant data is observational (endogenous levels) or extrapolated from in vitro MIC values and rodent models. Broad-spectrum antimicrobial and immunomodulatory activity well-established in basic science; exogenous therapeutic use unvalidated in humans.
PMC11858525 (2025): comprehensive structure-to-application review; PMID 14556006 (Ganz 2003): foundational antimicrobial peptide review; PMC11981803 (2025): HNP-1 activates SaeRS virulence system in S. aureus
Zero Phase I/II/III clinical data. Manufacturing barrier: three intramolecular disulfide bonds require expensive synthetic chemistry. No formal PK study in any species for SC route. Critical HIV paradox: HNP-1 both inhibits cell-free HIV (PMID 15681380) and increases HIV mucosal traversal (PMID 26379091). High-dose sepsis worsening (PMC9355784) complicates use in any infection context.
No organized self-experimentation community found. Fewer than 20 Reddit threads, all academic/discussion rather than protocol-sharing. No anecdotal dosing reports, stacking logs, or outcome data. This compound exists solely in research contexts.
Research exists (1,000+ papers on defensin biology) but no community self-experimentation exists. All dosing tiers are researcher-extrapolated estimates from in vitro MIC data, not real-world validated.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | 3x/week |
| Moderate | 100mcg | Daily |
| Aggressive | 200mcg | Daily |
HNP-1 is not something you'll find at a standard peptide vendor. Research-grade material from Bachem or AnaSpec runs roughly $250 to $400 per 0.1 mg. That price is telling you something about manufacturing difficulty. Reconstitution math for a 1 mg vial: add 2 mL bacteriostatic water to get 500 mcg/mL. A 50 mcg beginner dose is 0.10 mL (10 units on a U-100 insulin syringe). A 100 mcg moderate dose is 0.20 mL (20 units). A 200 mcg aggressive dose is 0.40 mL (40 units). Swirl gently when reconstituting. Defensins aggregate at air-water interfaces; shaking or vortexing will ruin your vial. If you see cloudiness after reconstituting, the product may be aggregated and should be discarded. Request a Certificate of Analysis with disulfide bond confirmation by mass spectrometry or NMR. Standard HPLC purity testing does not confirm the three disulfide bonds formed correctly. Misfolded HNP-1 is inactive or potentially cytotoxic. Get baseline bloodwork before starting: CBC with differential, CRP, ESR, and liver function panel.
No established human cycling protocols exist. The 8-on/4-off recommendation is conservative and based on general immune peptide cycling principles. Monitor inflammatory markers (CRP, ESR) during use. Discontinue if signs of excessive inflammation develop.
Exogenous HNP-1 is an endogenous human peptide, but supraphysiological exogenous administration can trigger anti-defensin antibodies that may alter endogenous innate immune function. Chronic pro-inflammatory cytokine elevation (TNF-α, IL-1β, IL-6) also warrants periodic washout to prevent cumulative endothelial and atherosclerotic risk. No receptor desensitization mechanism is established.
Or use the universal Peptide Calculator for any peptide.
Expected: Theoretical: enhanced innate immune activation (macrophage, DC, NK cell priming). No validated human outcome data exists. Observable markers: CBC with differential, inflammatory cytokines (TNF-α, IL-1β) if lab monitoring enabled.
Monitor: CBC with differential at baseline and week 4/8. CRP and ESR at baseline and week 4. Liver function panel recommended given PMC9355784 liver junction disruption finding at high doses.
Inject slowly against the inner wall of the vial containing 1 mg lyophilized HNP-1. This yields a concentration of 500 mcg/mL.
Do not shake, vortex, or invert vigorously. Defensins aggregate at air-water interfaces. A clear solution confirms proper reconstitution.
Beginner: 10 units (50 mcg). Moderate: 20 units (100 mcg). Aggressive: 40 units (200 mcg).
Rotate sites with each injection to minimize local tissue irritation from the cationic charge.
Use a 29 to 31 gauge needle (most insulin syringes come with 30 gauge). Pinch a fold of skin, insert at a 45-degree angle, inject slowly. Hold for 5 seconds before withdrawing.
Morning is commonly chosen for immune peptides, though no HNP-1-specific timing data exists.
Start at the beginner dose (50 mcg, 3 times per week) for the first 1 to 2 weeks. Only increase to daily 100 mcg if no excessive injection site inflammation develops.
Store reconstituted vials upright in the refrigerator at 2 to 8 degrees C. Use within 14 days. Do not freeze reconstituted solution.
Get bloodwork at baseline, week 4, and week 8 (CBC with differential, CRP, ESR, liver panel).
Complementary immune modulation via different pathway (thymic T-cell maturation vs. neutrophil/innate priming). TA-1 has actual human trial data (hepatitis B/C, cancer immune support) making the stack more grounded than HNP-1 alone.
TA-1 0.5–1.6 mg SC 2×/week alongside conservative HNP-1 protocol; monitor additive inflammatory signals
Cathelicidin AMP with overlapping antimicrobial/immunomodulatory activity; distinct receptor targets (FPRL1/FPR2 vs. CCR6). Both are endogenous host defense peptides with theoretical innate immune synergy.
LL-37 100–200 mcg SC daily alongside conservative HNP-1 dosing; monitor additive inflammatory signals closely
HNP-1 activates macrophages and promotes pro-inflammatory cytokines via NF-κB, directly opposing immunosuppressive therapy. In transplant recipients, risks graft rejection.
Do not combineHNP-1 neutralizes heparin's anticoagulant activity through direct binding. May unpredictably alter anticoagulation parameters.
Do not combineCombined immune activation effects unstudied. Theoretical risk of excessive immune activation or cytokine storm from dual checkpoint + innate immune stimulation.
The most serious concern with exogenous HNP-1 is host cell cytotoxicity. At high concentrations, alpha-defensins damage mammalian epithelial and endothelial cell membranes through the same pore-forming mechanism they use on microbes. This is concentration-dependent, not idiosyncratic. Higher doses mean more membrane disruption, and there is no established safe ceiling in humans. A mouse study (PMC9355784) found that high-dose exogenous HNP-1 at 10 mg/kg i.p. disrupted liver interendothelial junctions through the NLRP3 inflammasome/caspase-1 pathway. Animals in that study had worsened sepsis outcomes. The dose was 175 to 3,500 times higher than research tiers listed here, but the mechanism is concerning enough that liver function monitoring (ALT, AST) is recommended even at conservative doses. Pro-inflammatory cytokine elevation is expected, not a side effect to be dismissed. HNP-1 activates NF-kB, driving TNF-alpha, IL-1beta, and IL-6 release. For someone with underlying autoimmune disease, this could trigger a flare. For anyone on immunosuppressive therapy, it directly opposes the mechanism of drugs like tacrolimus and cyclosporine. Injection site reactions are predicted based on the peptide's cationic charge. Redness, swelling, and pain at the injection site reflect local tissue interaction with a positively charged peptide. If injection site inflammation becomes excessive, that signals local cytotoxicity, not an allergic reaction. Reducing dose or frequency is the appropriate response. The HIV paradox is not theoretical. HNP-1 kills cell-free HIV in laboratory assays [1]. But Demirkhanyan et al. (2012)[2] and a 2015 study [3] showed that HNP-1 disrupts epithelial tight junctions, increasing HIV traversal of mucosal barriers. Anyone who is HIV-positive or at high risk of HIV exposure should consider this an absolute contraindication. Raised endogenous defensin levels have been associated with atherosclerosis and endothelial dysfunction in observational studies. Extended exogenous use could theoretically worsen cardiovascular risk, particularly in someone with existing vascular disease. No formal human adverse event profiles exist. HNP-1 has never entered a Phase I trial. The total number of humans who have received exogenous HNP-1 as a therapeutic agent is effectively zero. When to stop: fever above 38 degrees C, any sign of worsening infection, autoimmune flare symptoms (joint pain, unexplained rash, disproportionate fatigue), liver enzymes rising above 2x the upper limit of normal, or any identified HIV exposure risk. Do not attempt to push through these signals. Pregnancy and breastfeeding: no reproductive safety data of any kind. This is a hard contraindication.
Verify Defensin (HNP-1) dosing and safety with a second opinion
HNP-1 requires three precisely-formed intramolecular disulfide bonds (Cys2-Cys30, Cys4-Cys19, Cys9-Cys29) that are critical for biological activity. Misfolded or partially oxidized product is biologically inactive or potentially cytotoxic, yet indistinguishable from active material by standard HPLC purity testing alone. Research-grade material is extremely expensive (~$250–400 per 0.1 mg from Bachem/AnaSpec/Sigma-Aldrich), effectively limiting the market to serious research labs. No compounded versions exist. Consumer/gray-market availability is essentially zero: this is not a standard peptide market item. The 2025 PMC11858525 review specifically cites production fidelity as the primary barrier to clinical translation.
| Test | When | Target |
|---|---|---|
| CBC with differential | Baseline, week 4, week 8 | WBC 4.5–11.0 K/µL; neutrophils 1.8–7.7 K/µL; no significant shift from baseline expected at research doses |
| C-Reactive Protein (CRP) | Baseline, week 2, week 4, week 8 | <3 mg/L baseline target; values >10 mg/L warrant dose reduction or discontinuation |
| Erythrocyte Sedimentation Rate (ESR) | Baseline, week 4, week 8 | <20 mm/hr (age-adjusted); rising trend warrants reassessment |
| Liver function panel (ALT, AST, ALP) | Baseline, week 4 | ALT <56 U/L, AST <40 U/L; any elevation >2× ULN warrants discontinuation |
Track neutrophil/monocyte/lymphocyte changes reflecting HNP-1 immunomodulation; detect unexpected cytopenias
HNP-1 stimulates pro-inflammatory cytokines (TNF-α, IL-1β via NF-κB); CRP monitors for excessive systemic inflammation
Secondary inflammatory marker; elevated in autoimmune and vasculitic conditions that HNP-1 could exacerbate
PMC9355784 finding: high-dose HNP-1 disrupts liver interendothelial junctions via NLRP3 inflammasome/caspase-1 pathway; hepatic monitoring warranted even at lower research doses
Treatment initiation at low dose. HNP-1 begins circulating and interacting with immune cells. Assess injection site tolerance and monitor for excessive local inflammation. Baseline bloodwork (CBC with differential, CRP, ESR) recommended.
Early immunomodulatory effects may begin. Neutrophil and monocyte activity may show subtle enhancement. Dendritic cell recruitment to peripheral tissues is theoretically increased.
Cumulative immune priming effects expected. In animal models, sustained defensin exposure produces measurable increases in macrophage phagocytic activity and dendritic cell maturation markers.
Peak treatment window. Adaptive immune bridging effects (T-cell recruitment, enhanced antigen presentation) should be most apparent. Full bloodwork recommended.
Week 1-2, Tolerance assessment: HNP-1 begins circulating after subcutaneous injection, with an estimated half-life of 3 to 4 hours. The cationic peptide interacts with local tissue at the injection site. Dendritic cell and monocyte chemoattraction through CCR6 binding theoretically starts during this window. Multiple injections per week are needed because the short half-life limits sustained immunomodulatory signaling. Expect injection site redness and mild swelling from the cationic charge interacting with local tissue. Mild flushing is possible from initial cytokine release. No human self-experimentation data exists for this compound; all expectations are extrapolated from animal models and peptide pharmacokinetic class data. Get baseline CBC with differential, CRP, and ESR before the first injection. Weeks 2-4, Early immunomodulatory effects (theoretical): Macrophage phagocytic activity may start to increase. Dendritic cell recruitment via CCR6 binding should be ongoing. NK cell activation is theoretically engaged at this point. All of these projections come from in vitro and rodent data only; no human validation exists. Zero community experience is available for comparison. Watch for pro-inflammatory cytokine effects: TNF-alpha and IL-1beta elevation could produce joint pain, rash, or fatigue in susceptible individuals. Weeks 4-8, Cumulative immune priming (animal model projection): Rodent studies show sustained defensin exposure produces measurable increases in macrophage phagocytic activity and dendritic cell maturation markers. The adaptive immunity effects (T-cell recruitment, improved antigen presentation) should be most apparent now. CRP and ESR monitoring is important during this phase; cumulative inflammatory load is a real concern. Observational data links raised HNP-1 to endothelial dysfunction, so extended use carries theoretical cardiovascular risk. Full bloodwork at week 4 and week 8, including liver function panel given the PMC9355784 finding on hepatic junction disruption at high doses.
HNP-1 circulates with estimated half-life of 3-4 hours. Electrostatic interaction with local tissue; initial DC/monocyte chemoattraction theoretically begins. Multiple injections per week required for sustained immunomodulatory signaling.
No human self-experimentation data: extrapolated from animal models and peptide PK class data only.
Macrophage phagocytic activity enhancement; dendritic cell recruitment via CCR6 binding; NK cell activation. All projections from in vitro and rodent data only: no human validation.
No reports: zero community experience available.
In rodent models, sustained defensin exposure produces measurable macrophage phagocytic upregulation and DC maturation marker increases. Adaptive immunity bridging (T-cell recruitment, enhanced antigen presentation) theoretically most apparent at this stage.
No reports available.
Source: No formal PK studies of exogenous HNP-1 in humans. Estimated 3-4 hours based on cationic peptide clearance kinetics for peptides in the 3-4 kDa range.
Loading the interactive decay curve.
HNP-1 holds research-only status with no FDA approval for any therapeutic indication. It has never entered a Phase I, II, or III clinical trial. The compound is available through research chemical suppliers (Bachem, AnaSpec, Sigma-Aldrich, CPC Scientific) for in vitro and animal research purposes. No compounding pharmacies produce HNP-1 formulations. The three disulfide bonds required for correct folding make production difficult and expensive, limiting availability to specialized chemical synthesis houses. WADA status for athletes is unclear. HNP-1 is an endogenous human peptide. However, exogenous administration of any immune-modulating substance could fall under prohibited methods depending on interpretation. Athletes subject to testing should verify current WADA guidelines before use. This content is for educational and research reference purposes only. It does not constitute medical advice. No information on this page should be interpreted as recommending the use of HNP-1 for any clinical purpose. Consult a qualified healthcare provider before making any decisions about peptide research or use.
Peptide Schedule Research TeamReviewed Apr 202610 Citations
